Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

This study has been completed.
Information provided by (Responsible Party):
Amgen Identifier:
First received: September 10, 2009
Last updated: February 7, 2017
Last verified: February 2017
Hyperparathyroidism (HPT) is common in people with a kidney transplant. Patients with HPT often have high parathyroid hormone (PTH) levels and may have large parathyroid glands in the neck. Patients with HPT can develop bone disease (osteodystrophy). This bone disease can cause bone pain, fractures, and poor formation of red blood cells. Other problems from HPT may include increases in blood levels of calcium (hypercalcemia) and low blood levels of phosphorus (hypophosphatemia). The high calcium levels may cause calcium to deposit in body tissues. Calcium deposits can cause arthritis (joint pain and swelling), muscle inflammation, itching, gangrene (death of soft tissue), heart and lung problems or kidney transplant dysfunction (worsening of kidney transplant function). The purpose of this study is to evaluate the effects of cinacalcet (Sensipar/Mimpara) on high calcium levels in the blood in patients with HPT after a kidney transplant.

Condition Intervention Phase
Chronic Allograft Nephropathy
Chronic Kidney Disease
Chronic Renal Failure
Disordered Mineral Metabolism
End Stage Renal Disease
Kidney Disease
Kidney Transplantation
Post Renal Transplantation
Drug: Cinacalcet
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism

Resource links provided by NLM:

Further study details as provided by Amgen:

Primary Outcome Measures:
  • Percentage of Participants With a Mean Corrected Total Serum Calcium Value < 10.2 mg/dL (2.55 mmol/L) During the Efficacy Assessment Phase (EAP) [ Time Frame: Weeks 21 to 26 (EAP) ]

Secondary Outcome Measures:
  • Percent Change From Baseline to Week 52 in Bone Mineral Density at the Femoral Neck [ Time Frame: Baseline and Week 52 ]
    Bone mineral density (BMD) was measured using dual X-ray absorptiometry (DXA).

  • Change From Baseline to the EAP in Mean Serum Phosphorus [ Time Frame: Baseline and the EAP (mean of Weeks 22, 24, and 26) ]
  • Change From Baseline to Week 52 in eGFR [ Time Frame: Baseline and Week 52 ]
    eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) formula.

  • Change From Baseline to the EAP in Corrected Total Calcium [ Time Frame: Baseline and the EAP (mean of Weeks 22, 24, and 26) ]
  • Change From Baseline to the EAP in Intact Parathyroid Hormone (iPTH) [ Time Frame: Baseline and the EAP (mean of Weeks 22, 24, and 26) ]
  • Change From Baseline to the EAP in Urine Phosphorus [ Time Frame: Baseline and the EAP (mean of Weeks 22, 24, and 26) ]
  • Percentage of Participants With a Parathyroidectomy [ Time Frame: 56 weeks ]
  • Time to Parathyroidectomy [ Time Frame: 56 weeks ]

Enrollment: 114
Study Start Date: December 2009
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cinacalcet
Participants received cinacalcet at a starting dose of 30 mg orally once daily for 52 weeks. Cinacalcet dose was titrated every 4 weeks during the dose-titration phase and during study visits in the maintenance phase based on intact parthyroid hormone (iPTH) values, corrected total serum calcium values, and safety assessments.
Drug: Cinacalcet
Possible sequential doses are 30, 60, 90, 120, and 180 mg.
Other Names:
  • Mimpara
  • Sensipar
Placebo Comparator: Placebo
Participants received placebo orally once daily for 52 weeks.
Drug: Placebo
Administered orally following the same dosing regimen as the experimental arm.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Received a kidney transplant ≥ 9 weeks at time of Screening and ≤ 24 months before first dose
  • May be the first kidney transplant or a repeat kidney transplant.
  • Subjects with a functional, stable kidney transplant, defined as MDRD estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m² (chromic kidney disease stage 3 or better) at Screening.
  • Men or women ≥ 18 years at the start of Screening (ie, time of informed consent).
  • Corrected total serum calcium > 10.5 mg/dL (2.63 mmol/L), defined as the mean of 2 values in Screening period.
  • iPTH > 100 pg/mL (10.6 pmol/L), during the Screening period (obtained at either Screen 1 or Screen 2).

Exclusion Criteria:

  • Received cinacalcet therapy post-transplant for more than 14 days cumulatively post-transplant. If cinacalcet therapy was received for a total of 14 days or less post-transplant, there must be a 4-week washout before subject is eligible for screening (Note: This does not exclude pre-transplant use of cinacalcet).
  • Anticipated parathyroidectomy within 6 to12 months after Randomization.
  • Ongoing therapy with bisphosphonates or use within 6 months prior to Screening.
  • Ongoing use of 1,25-dihydroxyvitamin D3 (including other active vitamin D metabolites or analogues) or use within 30 days prior to Screening.
  • Ongoing use of calcium supplements or use within 30 days prior to Screening.
  • Ongoing use of phosphate binders (calcium or non-calcium containing) or use within 30 days prior to Screening.
  • Ongoing use of a thiazide diuretic.
  • Subjects with a history of seizures who had a seizure within the 3 months prior to Randomization, which required adjustments to the seizure medication.
  • Acute Kidney Injury (AKI) or renal biopsy within 6 weeks prior to Screening, unless it is an institutional protocol-driven biopsy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00975000

  Show 51 Study Locations
Sponsors and Collaborators
Study Director: MD Amgen
  More Information

Additional Information:
Responsible Party: Amgen Identifier: NCT00975000     History of Changes
Other Study ID Numbers: 20062007
Study First Received: September 10, 2009
Results First Received: December 23, 2015
Last Updated: February 7, 2017

Keywords provided by Amgen:
acute rejection
kidney transplant failure

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Kidney Failure, Chronic
Renal Insufficiency
Urologic Diseases
Parathyroid Diseases
Endocrine System Diseases
Phosphorus Metabolism Disorders
Metabolic Diseases
Calcium Metabolism Disorders
Water-Electrolyte Imbalance
Cinacalcet Hydrochloride
Calcimimetic Agents
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on April 24, 2017